|
Individualised Tumor Response Testing (ITRT) or Drug Sensitivity Testing -- Information Sheet
for Patients
Who are we?
Bath Cancer Research is a charitably funded research group based at
the Royal United Hospital in Bath. Research scientist Dr Andrew Bosanquet,
who has been actively involved in the field of Individualised Tumor Response Testing for more
than twenty-five years, heads the team.
What do we do?
We aim to improve treatment for patients with leukaemia and lymphoma.
Patients with the same malignancy may vary in their response to treatment,
making it difficult for doctors to choose the best treatment for an individual.
To tackle this problem, we test malignant cells from individual patients
with a range of drugs to find each patient’s unique drug sensitivity
profile. We call this Individualised Tumor Response Testing (ITRT). ITRT Homepage. Test-sensitive drugs are four times more likely to be of benefit (improve the probability of response and/or survival)
than test-resistant drugs.
We use a test called the Tumour Response to Anti-neoplastic Compounds (TRAC) assay, a development of the Differential Staining Cytotoxicity (DiSC) assay. Our laboratories have accreditation to ISO 15189:2003 through CPA Ltd. for the Individualised Tumor Response test we perform.
What specimens do we test?
We routinely test leukaemias and lymphomas because malignant cells
are readily available from blood, bone marrow or lymph nodes. We have
most experience with chronic lymphocytic leukaemia (CLL), acute myeloid
leukaemia (AML), non-Hodgkin's lymphoma (NHL) and similar diseases. We
no longer test solid tumours. Please visit http://weisenthal.org for other
testing laboratories.
What do we need for a successful test?
We need live tumour cells that arrive in our laboratories as soon
as possible, and preferably within 24 hours of being taken. If enough
malignant cells are present we provide drug sensitivity results for over
95% of specimens. We aim to find drugs that will kill your malignant cells.
Your cells might not respond to any drug tested, especially if you have
a drug resistant tumour - even the best anticancer drugs do not work for
all patients. Sometimes no chemotherapy, or treatment with a new drug
that is effective in the test, is suggested by the test results.
Your doctor will always make suggestions as to how to treat your disease
based on a number of different factors, not just individualised tumor response test
results.
What if I want an Individualised Tumor Response test?
Ask your specialist, who can arrange for a specimen to be sent to
us. If cancer cells are only accessible by surgery, discuss post-operative
chemotherapy and individualised tumor response test options before your operation.
We will send an individualised tumor response test report, outlining your individual drug
response profile, to your doctor. If required, we will send your doctor
our "Information Sheet for Clinicians".
What does a Individualised Tumor Response test cost?
Individualised tumor response tests for other NHS patients
will generally cost £395.00 to test the sensitivity to 20+ cytotoxic drugs.
Private patients and those from abroad -
please enquire.
Cheaper, individualised tumor response tests are available for CLL. These
allow physicians to test the main cytotoxic drugs of interest at
diagnosis and also after the patients first regimen:
TRAC-0 suggested for untreated CLL patients
- testing five drugs for just £95.00 (Euros 150.00). Drugs tested:
fludarabine, cyclophosphamide, mitoxantrone, chlorambucil, methylprednisolone.
TRAC-1 suggested for CLL patients at first
relapse - testing 10 drugs and costing £195.00 (Euros 300.00).
Click here
for further details.
It costs £150,000 pa to run Bath Cancer Research. Donations
are always welcome!
Copyright © Bath Cancer Research 2000-2008
Date last modified: 11/2/08.
Webmaster: webmaster@caltri.org
[Home]
|
Home